BRPI0601285A - uso de agomelatina na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares - Google Patents

uso de agomelatina na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares

Info

Publication number
BRPI0601285A
BRPI0601285A BRPI0601285-0A BRPI0601285A BRPI0601285A BR PI0601285 A BRPI0601285 A BR PI0601285A BR PI0601285 A BRPI0601285 A BR PI0601285A BR PI0601285 A BRPI0601285 A BR PI0601285A
Authority
BR
Brazil
Prior art keywords
treatment
agomelatine
bipolar disorder
bipolar disorders
obtain medicines
Prior art date
Application number
BRPI0601285-0A
Other languages
English (en)
Inventor
Christian De Bodinat
Elisabeth Mocaer
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0601285(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of BRPI0601285A publication Critical patent/BRPI0601285A/pt
Publication of BRPI0601285A8 publication Critical patent/BRPI0601285A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"USO DE AGOMELATINA NA OBTENçãO DE MEDICAMENTOS DESTINADOS AO TRATAMENTO DE DISTúRBIOS BIPOLARES". A presente invenção refere-se ao uso de agomelatina, ou N-¢2-(7-metóxi-1-naftil)etil!acetamida, por si só, ou em associação, na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares, especialmente distúrbios bipolares dos tipos I e II, e mais especialmente distúrbios bipolares do tipo I.
BRPI0601285A 2005-04-20 2006-04-20 uso de agomelatina na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares BRPI0601285A8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0503937A FR2884714B1 (fr) 2005-04-20 2005-04-20 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires

Publications (2)

Publication Number Publication Date
BRPI0601285A true BRPI0601285A (pt) 2006-12-19
BRPI0601285A8 BRPI0601285A8 (pt) 2021-03-30

Family

ID=35311309

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0601285A BRPI0601285A8 (pt) 2005-04-20 2006-04-20 uso de agomelatina na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares

Country Status (41)

Country Link
US (1) US7947743B2 (pt)
EP (1) EP1714647B1 (pt)
JP (2) JP4580364B2 (pt)
KR (2) KR100835451B1 (pt)
CN (2) CN1853619B (pt)
AP (1) AP2656A (pt)
AR (1) AR057277A1 (pt)
AT (1) ATE491443T1 (pt)
AU (1) AU2006201655B2 (pt)
BR (1) BRPI0601285A8 (pt)
CA (1) CA2544136C (pt)
CR (1) CR9426A (pt)
CY (1) CY1111257T1 (pt)
DE (1) DE602006018822D1 (pt)
DK (1) DK1714647T3 (pt)
EA (1) EA013462B1 (pt)
ES (1) ES2357901T3 (pt)
FR (1) FR2884714B1 (pt)
GE (1) GEP20094651B (pt)
GT (1) GT200600141A (pt)
HR (1) HRP20110083T1 (pt)
IL (1) IL186373A (pt)
JO (1) JO2666B1 (pt)
MA (1) MA28266A1 (pt)
ME (1) ME01951B (pt)
MY (1) MY143171A (pt)
NO (1) NO336010B1 (pt)
NZ (1) NZ546630A (pt)
PE (1) PE20061337A1 (pt)
PL (1) PL1714647T3 (pt)
PT (1) PT1714647E (pt)
PY (1) PY0610113A (pt)
RS (1) RS51659B (pt)
SG (1) SG126868A1 (pt)
SI (1) SI1714647T1 (pt)
TN (1) TNSN07364A1 (pt)
TW (2) TW200940049A (pt)
UA (1) UA83681C2 (pt)
UY (1) UY29470A1 (pt)
WO (1) WO2006111653A1 (pt)
ZA (1) ZA200603160B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890563B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
US7608737B2 (en) 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2856934A1 (en) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarkers for the prediction of long term remission in depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5585118A (en) * 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
EP1368021B1 (en) * 2001-02-27 2007-11-14 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
JP2007517040A (ja) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法

Also Published As

Publication number Publication date
SG126868A1 (en) 2006-11-29
IL186373A0 (en) 2008-08-07
GT200600141A (es) 2006-11-22
EP1714647A1 (fr) 2006-10-25
AP2656A (en) 2013-05-07
US7947743B2 (en) 2011-05-24
FR2884714A1 (fr) 2006-10-27
EA013462B1 (ru) 2010-04-30
HK1093906A1 (en) 2007-03-16
IL186373A (en) 2012-06-28
JP2010280699A (ja) 2010-12-16
MY143171A (en) 2011-03-31
KR20060110803A (ko) 2006-10-25
CN1853619B (zh) 2011-02-02
CY1111257T1 (el) 2015-08-05
ME01951B (me) 2011-10-31
MA28266A1 (fr) 2006-11-01
NO336010B1 (no) 2015-04-20
AR057277A1 (es) 2007-11-28
ES2357901T3 (es) 2011-05-03
DE602006018822D1 (de) 2011-01-27
PE20061337A1 (es) 2007-01-27
TNSN07364A1 (en) 2008-12-31
EP1714647B1 (fr) 2010-12-15
ZA200603160B (en) 2007-06-27
UY29470A1 (es) 2006-05-31
KR20080028389A (ko) 2008-03-31
HRP20110083T1 (hr) 2011-03-31
CA2544136A1 (fr) 2006-10-20
JO2666B1 (en) 2012-06-17
BRPI0601285A8 (pt) 2021-03-30
CN102038669A (zh) 2011-05-04
DK1714647T3 (da) 2011-03-07
US20060240127A1 (en) 2006-10-26
PY0610113A (es) 2011-01-03
JP4580364B2 (ja) 2010-11-10
PL1714647T3 (pl) 2011-05-31
JP2006316056A (ja) 2006-11-24
TW200940049A (en) 2009-10-01
FR2884714B1 (fr) 2011-05-06
CN1853619A (zh) 2006-11-01
CR9426A (es) 2008-02-21
TW200716083A (en) 2007-05-01
NO20061705L (no) 2006-10-23
AP2007004212A0 (en) 2007-10-31
GEP20094651B (en) 2009-03-25
TWI318115B (en) 2009-12-11
ATE491443T1 (de) 2011-01-15
WO2006111653A1 (fr) 2006-10-26
AU2006201655A1 (en) 2006-11-09
RS51659B (sr) 2011-10-31
CA2544136C (fr) 2012-02-21
JP5341037B2 (ja) 2013-11-13
EA200600600A1 (ru) 2006-10-27
NZ546630A (en) 2007-09-28
PT1714647E (pt) 2011-01-14
SI1714647T1 (sl) 2011-03-31
UA83681C2 (uk) 2008-08-11
AU2006201655B2 (en) 2009-04-23
KR100835451B1 (ko) 2008-06-09

Similar Documents

Publication Publication Date Title
BRPI0701601A (pt) uso de agomelatina na obtenção de medicamentos previstos para o tratamento do dirtúrbio de ansiedade generalizada
TW200716208A (en) Modified and immediate release memantine bead formulation
BR9912179A (pt) Composição neuroprotetora para a prevenção e/ou tratamento de alterações nervosas e do comportamento devido a estados de ansiedade ou depressão
BRPI0603762A (pt) uso de agomelatina para obtenção de medicamentos intencionados para o tratamento de distúrbios de sono em pacientes deprimidos
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
AR041891A1 (es) Empleo de resveratrol para la preparacion de un medicamento util para el tratamiento de infecciones causadas por el virus de la influenza
BRPI0601285A (pt) uso de agomelatina na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
EA200702318A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения синдрома смита-магениса
BR0002772A (pt) Uso de ligantes melatoninérgicos na obtenção de composições farmacêuticas pretendidas para a prevenção ou o tratamento de patologias do sistema gastrintestinal
BR0210007A (pt) Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central
BRPI0704179A (pt) uso de agomelatina na obtenção de medicamentos pretendidos para o tratamento de leucomalacia periventricular
ATE399544T1 (de) Synergistische zusammensetzung enthaltend roflumilast und (r,r)-formoterol
CU20070232A7 (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento de los trastornos bipolares
MD2491G2 (ro) Utilizarea bromurii de S-etilizotiouroniu (izoturonului) pentru tratamentul algodismenoreii
NO20064049L (no) Ny assosiasjon mellom agomelatin og et tymoregulerende middel og farmasoytiske sammensetninger inneholdende den
BR0108823A (pt) Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: C07C 233/18 (2006.01), A61P 25/18 (2006.01), A61P

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 1876 DE 19/12/2006, QUANTO AO ITEM (32).

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2622 DE 06-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.